title: Induction of nicotinamide-adenine dinucleotide phosphate oxidase and apoptosis by biodegradable polymers in macrophages: implications for stents.
abstract: The drug-eluting stent platform has a limited surface area, and a polymer carrier matrix is coated to enable sufficient loading of drugs. The development of a suitable polymer has been challenging because it must exhibit biocompatibility with the intravascular milieu. The use of biodegradable polymers seems to be attractive because it enables drug release as it degrades and is eventually eliminated from the body leaving the permanent metallic stent polymer-free. The aim of this study was to investigate the biocompatibility of biodegradable polymers using the human monocyte cell line. Cultured monocytes differentiated into functional macrophages (THP-1) were incubated with various polymers including poly-L-lactide (PLA), polycaprolactone (PCL), or poly-D, L-lactide-co-glycolide (PLGA) for up to 5 days. Exposure of cells to the polymers resulted in macrophage-polymer adhesion and induced marked pro-oxidant species as measured by calcein AM uptake assay and flow cytometric analysis of 2',7'-dichlorofluorescin fluorescence, respectively. Real-time reverse-transcription polymerase chain reaction and Western blot analysis of expression of nicotinamide-adenine dinucleotide phosphate (NADPH) oxidases revealed enhanced expression of NADPH oxidase subunits in response to PLA and PLGA compared with that of PCL. Flow cytometric analysis of fluorescein isothiocyanate-Annexin V and propium iodide-stained PLA and PGLA polymer-exposed THP-1 cells showed early and late apoptotic changes. Similarly, exposure to the PLA and PGLA polymers, but not to the PCL polymer, resulted in enhanced staining for cleaved poly(ADP-ribose) polymerase-1, a protein fragment produced by caspase cleavage. These results indicate that biodegradable polymers are associated with cell adhesion, NADPH oxidase-induced generation of reactive oxygen species and excess apoptosis.
authors: Division of Biology, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD 20993-0002, USA. pushya.potnis@fda.hhs.gov
authors: Pushya A
authors: PA
authors: Potnis
authors: Belay
authors: B
authors: Tesfamariam
authors: Steven C
authors: SC
authors: Wood
mesh_terms: D020341:Absorbable Implants / Q000009:adverse effects*; D017209:Apoptosis; D002448:Cell Adhesion; D002460:Cell Line; D054855:Drug-Eluting Stents; D004790:Enzyme Induction; D005786:Gene Expression Regulation; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D007700:Kinetics; D008264:Macrophages / Q000201:enzymology / Q000378:metabolism*; D019255:NADPH Oxidases / Q000096:biosynthesis* / Q000235:genetics; D011091:Polyesters / Q000009:adverse effects* / Q000378:metabolism; D011098:Polyglactin 910 / Q000009:adverse effects / Q000378:metabolism; D021122:Protein Subunits / Q000096:biosynthesis / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D018836:Inflammation Mediators; D011091:Polyesters; D021122:Protein Subunits; D012333:RNA, Messenger; D017382:Reactive Oxygen Species; C016240:polycaprolactone; D011098:Polyglactin 910; C033616:poly(lactide); D019255:NADPH Oxidases